SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 108.91 |
| Enterprise Value ($M) | -81.40 |
| Book Value ($M) | 44.60 |
| Book Value / Share | 0.53 |
| Price / Book | 2.44 |
| NCAV ($M) | 0.70 |
| NCAV / Share | 0.01 |
| Price / NCAV | 154.70 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.36 |
| Return on Assets (ROA) | -0.56 |
| Return on Equity (ROE) | -2.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.60 |
| Current Ratio | 2.60 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 343.31 |
| Assets | 387.21 |
| Liabilities | 342.61 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 62.04 |
| Operating Income | -238.45 |
| Net Income | -227.46 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -191.54 |
| Cash from Investing | 218.51 |
| Cash from Financing | 94.05 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 7.30 | 5.49 | |
| 13G | Ra Capital Management, L.p. | 5.30 | ||
| 13G/A | Point72 Asset Management, L.P. | 3.70 | -49.48 | |
| 13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 | |
| 13G/A | Rubric Capital Management LP | 0.00 | -100.00 | |
| 13G/A | Adage Capital Management, L.P. | 2.75 | ||
| 13G/A | Vanguard Group Inc | 5.11 | 0.00 | |
| 13G/A | Integrated Core Strategies (us) Llc | 2.50 | -41.14 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,492,682 | 5,544,727 | 44.96 | |
| 1,500,570 | 4,188,267 | 35.83 | |
| 658,309 | 2,934,180 | 22.44 | |
| 1,270,079 | 5,271,583 | 24.09 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SKYE – Skye Bioscience, Inc. | SMMT – Summit Therapeutics Inc. |
| SPRY – ARS Pharmaceuticals, Inc. | SUPN – Supernus Pharmaceuticals, Inc. |
| TARA – Protara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io